GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Starry Pharmaceutical Co Ltd (SHSE:603520) » Definitions » Purchase Of Property, Plant, Equipment

Zhejiang Starry Pharmaceutical Co (SHSE:603520) Purchase Of Property, Plant, Equipment : ¥-254 Mil (TTM As of Jun. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Zhejiang Starry Pharmaceutical Co Purchase Of Property, Plant, Equipment?

Zhejiang Starry Pharmaceutical Co's purchase of property, plant, equipment for the three months ended in Jun. 2024 was ¥-56 Mil. It means Zhejiang Starry Pharmaceutical Co spent ¥56 Mil on purchasing property, plant, equipment. Zhejiang Starry Pharmaceutical Co's purchase of property, plant, equipment for the trailing twelve months (TTM) ended in Jun. 2024 was ¥-254Mil.

Compared with last quarter (¥-97 Mil in Mar. 2024 ), Zhejiang Starry Pharmaceutical Co spent less money on purchasing property, plant, equipment in Jun. 2024 (¥-56 Mil).

Zhejiang Starry Pharmaceutical Co Purchase Of Property, Plant, Equipment Historical Data

The historical data trend for Zhejiang Starry Pharmaceutical Co's Purchase Of Property, Plant, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Starry Pharmaceutical Co Purchase Of Property, Plant, Equipment Chart

Zhejiang Starry Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Purchase Of Property, Plant, Equipment
Get a 7-Day Free Trial Premium Member Only Premium Member Only -133.28 -153.17 -303.88 -472.18 -266.23

Zhejiang Starry Pharmaceutical Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Purchase Of Property, Plant, Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -85.46 -49.02 -51.89 -96.58 -56.46

Zhejiang Starry Pharmaceutical Co Purchase Of Property, Plant, Equipment Calculation

The amount used to purchase PPE.

Purchase Of Property, Plant, Equipment for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-254 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Starry Pharmaceutical Co Purchase Of Property, Plant, Equipment Related Terms

Thank you for viewing the detailed overview of Zhejiang Starry Pharmaceutical Co's Purchase Of Property, Plant, Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhejiang Starry Pharmaceutical Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Starry Pharmaceutical Co Ltd (SHSE:603520) » Definitions » Purchase Of Property, Plant, Equipment
Comparable Companies
SHSE:688247 SZSE:300485 SZSE:300110 SZSE:002644 SHSE:600488 SZSE:002393 SZSE:300194 SZSE:300401 SZSE:300636 SHSE:603998 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
No.1 Sitali Avenue, Modern Industrial Gathering District, Zhejiang Province, Xianju County, Taizhou City, CHN, 317306
Website
http://www.starrypharm.com
Zhejiang Starry Pharmaceutical Co Ltd is engaged in R&D, manufacture and marketing of active ingredient and intermediate X-CT non-ionic contrast agent series and Fluoroquinolones series.
Executives
Hu Jin Sheng Director

Zhejiang Starry Pharmaceutical Co Headlines

No Headlines